Market revenue in 2024 | USD 738.8 million |
Market revenue in 2035 | USD 2,487.5 million |
Growth rate | 10.2% (CAGR from 2025 to 2035) |
Largest segment | Ozempic (semaglutide) |
Fastest growing segment | Wegovy (semaglutide) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2035 |
Quantitative units | Revenue in USD million |
Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 54.62% in 2024. Horizon Databook has segmented the Germany semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
Germany leads the Europe market due to its advanced biopharmaceutical manufacturing and robust healthcare system. Increasing adoption of GLP-1 receptor agonists for metabolic disorders and obesity fuels growth.
Hospital pharmacies dominate the distribution landscape, with online pharmacy expansion improving patient access to semaglutide-based therapies.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany semaglutide market , including forecasts for subscribers. This country databook contains high-level insights into Germany semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account